NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Tarceva® (erlotinib): First-line maintenance indication now restricted to treatment of patients whose tumours harbour an EGFR-activating mutation

Kadar pengguna: 2 / 5

bintang aktifbintang aktifBintang tidak aktifBintang tidak aktifBintang tidak aktif
 

Date: 1 July 2016

 

Description:

Tarceva® (erlotinib) is no longer indicated for the first-line maintenance treatment in patients without an epidermal growth factor receptor (EGFR)-activating mutation based on data from the IUNO study. The results of the IUNO study led to the conclusion that the benefit-risk of Tarceva® is no longer considered favourable for maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after 4 cycles of standard platinum-based first-line chemotherapy whose tumours do not harbour an EGFR-activating mutation. Please refer to the DHPC issued by Roche (Malaysia) Sdn. Bhd. for further information.

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Jumaat 20 Disember 2024, 19:30:56.

Search